Company intelligence / Profile preview

MyHeartBeat

Ownership: Private
Development stage: Other

Overview

HeartBeat.bio is developing novel medicines for heart failure using a proprietary human cardiac organoid platform. Their approach enables more physiologically relevant drug discovery compared to animal models. The company’s programs are in preclinical stages, focusing on reversing or halting myocardial fibrosis and remodeling—key drivers of heart failure progression.

Therapeutic areas: Cardiovascular
Modalities: Small moleculeNucleotide-based modulator
Industry: Biotech

Partnerships

Collaborations with pharmaceutical and biotechnology companies to develop new preclinical compoundsPartnerships with technology providers in assay development, high-throughput screening, data analytics, AI-driven drug discovery

Beyond the preview

Go deeper on MyHeartBeat.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MyHeartBeat.

Explore the full profile